Bank of New York Mellon Corp Has $832,000 Position in Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 4.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,720 shares of the biotechnology company’s stock after buying an additional 3,693 shares during the period. Bank of New York Mellon Corp owned about 0.19% of Capricor Therapeutics worth $832,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Nuveen Asset Management LLC boosted its position in Capricor Therapeutics by 392.7% during the 4th quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company’s stock worth $2,334,000 after acquiring an additional 134,791 shares during the period. Alliancebernstein L.P. acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth approximately $183,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 2,361 shares during the period. Two Sigma Investments LP grew its position in Capricor Therapeutics by 223.6% during the fourth quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company’s stock valued at $1,643,000 after purchasing an additional 82,254 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Capricor Therapeutics by 37.8% in the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock valued at $12,139,000 after buying an additional 241,279 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 3.4%

CAPR opened at $7.90 on Friday. The stock’s 50 day simple moving average is $9.82 and its 200-day simple moving average is $11.41. The stock has a market cap of $360.87 million, a PE ratio of -5.56 and a beta of 0.59. Capricor Therapeutics, Inc. has a 1 year low of $3.52 and a 1 year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same period last year, the company earned ($0.31) EPS. Equities analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CAPR. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. HC Wainwright lowered their target price on Capricor Therapeutics from $77.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, July 11th. Oppenheimer dropped their target price on Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, June 23rd. Roth Capital cut their price target on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, July 14th. Finally, Piper Sandler reissued an “overweight” rating and issued a $20.00 price target on shares of Capricor Therapeutics in a research note on Friday, July 11th. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.56.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.